Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-Current Assets (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Non-Current Assets for 6 consecutive years, with $25.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 7.8% to $25.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.4 million through Dec 2025, down 8.5% year-over-year, with the annual reading at $25.7 million for FY2025, 7.8% down from the prior year.
  • Non-Current Assets for Q4 2025 was $25.7 million at Janux Therapeutics, down from $26.7 million in the prior quarter.
  • The five-year high for Non-Current Assets was $32.2 million in Q2 2023, with the low at $215000.0 in Q2 2021.
  • Average Non-Current Assets over 5 years is $23.6 million, with a median of $27.8 million recorded in 2024.
  • The sharpest move saw Non-Current Assets soared 12597.67% in 2022, then dropped 10.64% in 2024.
  • Over 5 years, Non-Current Assets stood at $2.8 million in 2021, then soared by 1025.53% to $31.6 million in 2022, then decreased by 1.28% to $31.2 million in 2023, then dropped by 10.64% to $27.8 million in 2024, then decreased by 7.8% to $25.7 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $25.7 million, $26.7 million, and $26.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.